YSI Biochemical Analysers Assist in Anti-tumour Research
Anti-cancer drug development is an important component of modern pharmacological research. One target for these drugs is the conversion of glutamine to glutamate because glutamine is an important energy source for many different types of tumour cells.
Obviously in order to test the efficacy of such drugs on tumour cell lines it is vital to be able to accurately and reliably measure both glutamine and glutamate, alongside other media components such as glucose and lactate.
Increasingly, the method of choice for these measurements is the YSI series of biochemical analysers. The proprietary immobilised enzyme technology can produce reliable and accurate results in under one minute, but is simple to use and maintain, thanks to intuitive touch screen operation and advanced anti-clogging design. The latest YSI model 2900M Monitoring and Control model also features online asceptic modelling and 96 well plate sampling.
One recent study into the action of the potent glutaminase inhibitor CB-839 made full use of the YSI 2900 Biochemical Analysers functionality. Glutaminase is a mitochondrial enzyme that converts glutamine to glutamate, the first step in glutamine utilisation.
In a study of antiproliferative activity in a triple-negative breast cancer (TNBC) cell line, HCC-1806 using the YSI analyser it was found that CB-839 decreased activity in a manner that was associated with a marked decrease in glutamine consumption and glutamate production. Alongside this there was a decrease in oxygen consumption and a number of tricarboxylic acid cycle intermediates. By comparison an oestrogen receptor–positive cell line, T47D, showed only modest effects on glutamine consumption and downstream metabolites when CB-839 was applied.
As CB-838 is orally bioavailable there are strong reasons for clinically investigating CB-839 in patients with glutamine-dependent tumours, as well as utilising the YSI Biochemical Analyser range in your oncological research.
Date added: 2015-05-25 14:29:36